NASDAQ · TKNOHealthcareDiagnostics

Alpha Teknova financials

$9.08−1.30%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
Revenue$40.5M$37.7M$36.7M$41.4M$36.9M
Gross profit$13.4M$7.2M$10.3M$17.5M$17.6M
Gross margin33.2%19.2%28.1%42.2%47.8%
Operating income-$17.0M-$26.1M-$35.6M-$49.7M-$12.0M
Net income-$17.3M-$26.7M-$36.8M-$47.5M-$9.8M
Net margin−42.6%−70.9%−100.3%−114.6%−26.6%
Diluted EPS$-0.32$-0.57$-1.16$-1.69$-0.61
EBITDA-$10.6M-$19.6M-$25.5M-$25.7M-$9.1M
Operating cash flow-$8.6M-$12.4M-$18.8M-$27.4M-$9.1M
Free cash flow-$9.8M-$13.5M-$26.7M-$55.5M-$28.9M
Diluted shares53.5M46.7M31.8M28.1M16.1M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$5.9M$3.7M$28.5M$42.2M$87.5M
Short-term investments$15.4M$26.7M$0.00$0.00—
Total debt$13.1M$13.5M$13.3M$22.0M$11.9M
Total assets$103.6M$118.8M$128.6M$152.3M$166.5M
Total liabilities$34.8M$36.4M$38.6M$52.4M$23.3M
Shareholders' equity$68.8M$82.4M$90.0M$99.9M$143.2M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology